We can’t show the full text here under this license. Use the link below to read it at the source.
Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study
Tirzepatide's effects in people with type 2 diabetes and fatty liver linked to metabolism
AI simplified
Abstract
Significant reductions in body weight, hemoglobin A1c (HbA1c), fatty liver index, FIB-4 index, and high-sensitivity C-reactive protein (hsCRP) levels were observed six months after switching to tirzepatide in 54 Japanese patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).
- Switching to tirzepatide was associated with improved outcomes in patients previously treated with either dulaglutide or semaglutide.
- Age, duration of type 2 diabetes, and HbA1c levels before the switch were identified as significant independent predictors of weight loss rate.
- Age prior to the switch may also serve as a predictor for a decrease in fatty liver index.
- The appetite suppression effect of tirzepatide was less pronounced in patients who had previously used semaglutide compared to those who used dulaglutide.
- Despite this, significant improvements in body weight, HbA1c levels, fatty liver index, and FIB-4 index were noted in both groups after the switch.
AI simplified